Biotech start-up pockets $8.7M in venture cash

Cellumen says it will use an $8.7 million injection of venture capital to begin its commercialization efforts. The company specializes in cellular systems biology for drug discovery work. Safeguard Scientifics provided $6 million of that while PA Early Stage Partners put up $2 million.

- see the release
- read the the Pittsburgh Business Journal report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.